Stocks and Investing
Stocks and Investing
Tue, May 8, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, May 7, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lebovitz Maintained (ALNY) at Hold with Decreased Target to $107 on, May 7th, 2018
David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $118 to $107 on, May 7th, 2018.
David has made no other calls on ALNY in the last 4 months.
There are 4 other peers that have a rating on ALNY. Out of the 4 peers that are also analyzing ALNY, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Stephen Willey of "Stifel" Maintained at Hold with Decreased Target to $95 on, Friday, May 4th, 2018
- Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $135 on, Thursday, January 25th, 2018
These are the ratings of the 2 analyists that currently disagree with David
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $134 on, Friday, May 4th, 2018
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $154 on, Tuesday, March 13th, 2018
Contributing Sources